Ray Camahort is a Partner at Novo Holdings Venture Investments. He has over 15 years of combined investment, business, and research experience, with expertise in biochemistry, genetics, and gene therapy/editing. Prior to joining Novo Ventures, Dr. Camahort worked in business development at the Harvard University Office of Technology Development where his role was to facilitate commercialization of technologies developed in the chemistry and stem cell/regenerative biology departments.
Dr. Camahort has served on the Board of Directors of numerous companies, including Arcellx, Inspirna, iECURE, Obsidian Therapeutics, and Ray Therapeutics. He completed a National Institute of Health post-doctoral training fellowship at Harvard University and was a pre-doctoral fellow at the Stowers Institute for Medical Research in Kansas City, Missouri. He holds a Ph.D. from the University of Kansas in biochemistry and molecular biology and a B.S. in biological sciences from the University of California Santa Barbara.